礼来公司旗下药物Ebglyss(Lebrikizumab-Lbkz)在针对6个月至18岁中重度特应性皮炎患者的三期临床试验中,成功达成预设研究目标。该药物由此成为全球首个且目前唯一在此年龄段患者群体中展现出积极疗效的选择性IL-13抑制剂。
礼来公司旗下药物Ebglyss(Lebrikizumab-Lbkz)在针对6个月至18岁中重度特应性皮炎患者的三期临床试验中,成功达成预设研究目标。该药物由此成为全球首个且目前唯一在此年龄段患者群体中展现出积极疗效的选择性IL-13抑制剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.